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Abstract
Background: The aim of this research was to study the epidemiology, microbiology, prophylaxis, and antibiotic
therapy of surgical site infections (SSIs), especially those caused by methicillin-resistant Staphylococcus aureus
(MRSA), and identify the risk factors for these infections. In Italy SSIs occur in about 5 % of all surgical procedures.
They are predominantly caused by staphylococci, and 30 % of them are diagnosed after discharge. In every surgical
specialty there are specific procedures more associated with SSIs.
Methods: The authors conducted a systematic review of the literature on SSIs, especially MRSA infections, and used
the Delphi method to identify risk factors for these resistant infections.
Results: Risk factors associated with MRSA SSIs identified by the Delphi method were: patients from long-term
care facilities, recent hospitalization (within the preceding 30 days), Charlson score > 5 points, chronic obstructive
pulmonary disease and thoracic surgery, antibiotic therapy with beta-lactams (especially cephalosporins and carbapenem)
and/or quinolones in the preceding 30 days, age 75 years or older, current duration of hospitalization >16 days, and
surgery with prothesis implantation. Protective factors were adequate antibiotic prophylaxis, laparoscopic surgery and the
presence of an active, in-hospital surveillance program for the control of infections. MRSA therapy, especially with agents
that enable the patient’s rapid discharge from hospital is described.
Conclusion: The prevention, identification and treatment of SSIs, especially those caused by MRSA, should be
implemented in surgical units in order to improve clinical and economic outcomes.
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Background
Surgical site infections (SSIs) remain a major clinical
problem in terms of morbidity, mortality, time spent in
hospital and overall direct and indirect costs [1–3].
Despite progress in their prevention, SSIs remain one of
the most common adverse events in hospitals, account-
ing for 11 % to 26 % of all healthcare-associated
infections [4]. Surgical patients can develop several post-
operative infections; wound infections, are common causes
of post-operative morbidity and prolonged hospitalization.
SSIs increase the total hospital bill by an additional 10–
20 % [5], lead to 80,000 deaths and are associated with an
annual treatment cost of two billion US dollars [6]. S.
aureus SSIs can be life-threatening, being associated with a
mortality rate of 5 %, more than 2 extra weeks of
time spent in hospital and around an extra cost of
50,000 US dollars [7].
Nearly 60 % of SSIs are diagnosed after discharge from
the hospital. This percentage is rising as the post-
operative stay in hospital is getting shorter and the num-
ber of 1-day surgical procedures is increasing over time
[8]. The Diagnosis Related-Group (DRG) system under-
estimates the rate of SSIs because of the very early dis-
charge of surgical patients. The exact incidence of SSIs
is, therefore, difficult to determine. According to current
literature, active SSI surveillance is useful in reducing
the incidence of SSIs by surveillance-induced infection
control efforts [9]. When any prosthesis is implanted
into the body during general surgery, cardiac surgery,
orthopaedics, etc., beside S. aureus, Coagulase-negative
Staphylococci, especially S. epidermidis, may be the
cause of severe infections that can necessitate removal
of the prosthesis.
Classification of surgical site infections
The identification of SSIs involves interpretation of clin-
ical and laboratory findings. The Centers for Disease
Control and Prevention’s (CDC) National Nosocomial
Infections Surveillance system has developed stan-
dardized surveillance criteria for defining SSIs [10].
According to these criteria, SSIs are classified as be-
ing either incisional or organ/space. Incisional SSIs
are further divided into those involving only skin and
subcutaneous tissue (superficial incisional SSIs) and
those involving deeper soft tissues of the incision
(deep incisional SSIs).
Superficial incisional surgical site infections
The infection occurs within 30 days after the operation
and involves only the skin or subcutaneous tissue at the
incision and at least one of the following:
1. purulent drainage, with or without laboratory
confirmation, from the superficial incision;
2. organisms isolated from an aseptically obtained
culture of fluid or tissue from the superficial
incision;
3. at least one of the following signs or symptoms of
infection: pain or tenderness, localized swelling,
redness, or heat; the site is deliberately opened by
the surgeon, unless ithe incision is culture-negative.
Deep incisional surgical site infections
The infection occurs within 30 days after the operation
if no implant is left in place or within 1 year if an im-
plant is left in the body and the infection appears to be
related to the operation and involves deep soft tissues
(e.g., fascial and muscle layers) at the incision site and at
least one of the following:
1. purulent drainage from the deep incision but not
from the organ/space component of the surgical site;
2. a deep incision spontaneously dehisces or is
deliberately opened by a surgeon when the patient
has at least one of the following signs or symptoms:
fever (>38 °C), localized pain, or tenderness, unless
the site is culture-negative.
3. an abscess or other evidence of infection involving
the deep incision is found on direct examination,
during reoperation, or by histopathological or
radiological examination.
Organ/space surgical site infections
The infection occurs within 30 days after the operation
if no implant is left in place or within 1 year if an im-
plant is left in the body and the infection appears to be
related to the operation and involves any part of the
anatomy (e.g., organs or spaces), other than the incision,
which was opened or manipulated during an operation
and at least one of the following:
1. purulent drainage from a drain that is placed
through a stab wound into the organ/space.
2. organisms isolated from an aseptically obtained
culture of fluid or tissue in the organ/space.
3. an abscess or other evidence of infection involving
the organ/space that is found on direct examination,
during reoperation, or by histopathological or
radiological examination.
Recently, the Food and Drug Administration (FDA)
proposed a new classification of skin and soft tissue in-
fections, namely acute bacterial skin and skin structure
infections (ABSSSIs), incorporating erysipelas, cellulitis,
major subcutaneous abscesses and wound infections in-
cluding SSIs. An ABSSSI is a bacterial infection of the
skin with a lesion area of at least 75 cm2, measured by
redness, edema, or induration [11]. ABSSSIs represent a
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significant burden for the health-care system, with in-
creasing incidence and severity in recent years, and they
have become a challenging medical problem associated
with high direct and indirect costs to both the medical
system and society. Among the various ABSSSIs, SSIs
caused by MRSA may have an important impact on hos-
pital budgets and on patients’ health. The rationale for
introducing this terminology was to provide a consistent
means of identifying infections for which a reliable drug
treatment effect can be estimated and of correctly strati-
fying patients with this kind of infection included in
clinical trials.
Microbiological epidemiology
According to the National Nosocomial Infection Surveil-
lance system reports, Gram-positive cocci (particularly S.
aureus, coagulase-negative staphylococci and Entero-
coccus spp.), followed by Escherichia coli, Pseudomonas
aeruginosa and Enterobacter spp., are the most com-
monly encountered pathogens in SSIs [12]. In most
cases, the source of pathogens is the endogenous flora of
the patient’s skin, mucous membranes, or hollow viscera
[13]. When mucous membranes or the skin are incised,
the exposed tissues are at risk of contamination by
endogenous flora [14]. These micro-organisms are
usually aerobic Gram-positive cocci (e.g., staphylococci),
but may include fecal flora (e.g., anaerobic bacteria and
Gram-negative aerobes) when incisions are made near the
perineum or groin. Exogenous sources of SSI pathogens
include surgical personnel (especially members of the
surgical team), the operating room environment
(including air), and all equipment, instruments, and
materials brought to the sterile field during an oper-
ation. Exogenous flora consists primarily of aerobes, es-
pecially Gram-positive organisms (e.g., staphylococci
and streptococci) [15].
Table 1 presents the more frequent pathogens accord-
ing to the surgical procedure.
Methicillin-resistant Staphylococcus aureus
Methicillin-resistant Staphylococcus aureus (MRSA) is a
versatile and dangerous bacterial pathogen, combining
virulence, antibiotic resistance, and survival fitness [16].
Its spread is facilitated by cross-transmission through
health-care workers’ hands and selection pressure exer-
cised by broad-spectrum antibiotic treatment. MRSA in-
fections represent a substantial burden, because they
increase treatment costs and can cause excess morbidity
and mortality. Since MRSA carriers without symptom-
atic infection are an important reservoir and source of
spread of infections, risk profiles to identify patients at
high risk of carrying MRSA might improve prevention
of MRSA infections [17].
The control of SSIs within the hospital is important,
as is identifying patients at risk of being colonized and
subsequently infected by multi-drug resistant microor-
ganisms such as MRSA; surveillance itself, even without
any specific intervention, has been associated with a
Table 1 More frequent pathogens according to the surgical procedure
Type of surgery Likely Pathogens
Placement of all grafts, prostheses, or implants S. aureus, coagulase negative staphylococci
Cardiac S. aureus, coagulase negative staphylococci
Neurosurgery S. aureus, coagulase negative staphylococci
Breast S. aureus, coagulase negative staphylococci
Ophthalmic (limited data, however, commonly used in procedures such as anterior
segment resection, vitrectomy, and scleral buckles)
S. aureus, coagulase negative staphylococci, streptococci,
gram-negative bacilli
Orthopedic (Total joint replacement, closed fractured/use of nails, bone plates,
other internal fixation device, functional repair without implant/device trauma)
S. aureus, coagulase negative staphylococci, gram-negative bacilli
Non-cardiac thoracic (lobectomy, pneumonectomy, wedge resection,
other non-cardiac mediastinal procedures) Closed tube thoracotomy
S. aureus, coagulase negative staphylococci, S. pneumoniae,
gram-negative bacilli
Vascular S. aureus, coagulase negative staphylococci
Appendectomy Gram-negative bacilli, anaerobes
Biliary tract Gram-negative bacilli, anaerobes
Colorectal Gram-negative bacilli, anaerobes
Gastroduodenal Gram-negative bacilli, streptococci, oropharyngeal anaerobes
(e.g. peptostreptococci)
Head and neck (majorly procedures with incision through oropharyngeal mucosa) S. aureus, streptococci, oropharyngeal anaerobes (e.g.
peptostreptococci)
Obstetric and gynecologic Gram-negative bacilli, enterococci, group B streptococci,
anaerobes
Urologic Gram-negative bacilli
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reduction in the incidence of SSIs, which is another
reason to recommend implementation of surveillance
systems [18].
According to the new ABSSSI classification, erysip-
elas and cellulitis are mostly due to Gram-positive or-
ganisms whereas SSIs and subcutaneous abscesses are
due to mixed flora including Gram-positive microbes.
The epidemiology of surgical site infections in Italy
In Italy the incidence rate of SSIs might be around 5 %
(Table 2). Hospitals without a surveillance system that
report rates less than 5 % probably underestimate the
problem. In fact many SSIs are diagnosed more than
30 days after surgery, when the patient has already been
discharged from hospital. The overall incidence rate of
SSIs in Italy in the past was higher, ranging from 5.4 %
up to 12.8 % [19, 20]. In Europe, considering only gen-
eral, gynecological (including Cesarean sections), and
vascular surgery, SSIs rates are higher and range from
6.34 % to 14.8 % [21].
Petrosillo et al. reported that SSIs occurred in 5.2 % of
4,665 patients. Of these SSIs, 148 (61.4 %) developed
during the patients’ stay in hospital, and 93 (38.6 %)
within 30 days after discharge. Of the 148 in-hospital
SSIs, 87, 37, and 24 were classified as superficial, deep,
and organ/space, respectively. Post-discharge SSIs ob-
served at medical follow-up were all superficial [21].
This study also produced information on post-
discharge SSIs; the authors found that 38.6 % of SSIs
were diagnosed after the patients’ discharge from hos-
pital; this rate is comparable to the 34.8 % reported by
Fiorio et al. [22] in Italian general surgery in-patients, al-
though other similar surveillance studies [23] found con-
siderably higher post-discharge SSIs rates, ranging from
34.8 % to 60 %.
Marchi et al. reported data on non-prosthetic surgery
from the Italian SSI surveillance program for the period
2009 to 2011. In the 355 surgical wards included in the
study, 60,460 operations were recorded. SSIs were ob-
served in 1,628 cases (2.6 %) and 60 % of the infections
were diagnosed through 30-day post-discharge surveil-
lance. Operations performed in hospitals with at least
2 years of surveillance showed a 29 % lower risk of SSIs,
confirming that surveillance is a protective factor for
preventing SSIs [24].
Table 3 reports the probability of developing a post-
discharge SSI according to type of surgery performed.
Used vascular surgery as the benchmark (0 % of infec-
tions after discharge) each number represents the prob-
ability of a post-discharge diagnosis of a SSI.
Specific types of surgical procedures and surgical site
infections
Hernia and abdominal wall surgery
Although this type of surgery is “clean and easy” to per-
form, the usual application of meshes might expose pa-
tients to a higher risk of SSIs.
According to the Italian Society of Hernia and Ab-
dominal Wall Surgery, 210,000 surgical procedures per
year are performed on the abdominal wall in Italy; this
kind of procedure is, therefore, the most common type
in Italy. These procedures comprise 170,000 inguinal
hernia repairs per year, and 40,000 parietal hernia re-
pairs, with this latter group including 20,000 incisional
hernias. Almost all of these procedures are performed
using meshes in order to reduce the incidence of recur-
rence and to achieve closure of the abdominal wall de-
fect avoiding abdominal hypertension and respiratory
complications. The use of meshes may increase the risk
of SSIs caused by difficult-to-treat microorganisms such
as S. aureus, coagulase-negative staphylococci and
multidrug-resistant nosocomial Gram-negative organism
[25], leading to infection of the mesh itself.
Despite hernia repairs being classified as “clean” opera-
tions, the use of synthetic material has been associated
with a theoretical increase in infectious risk. Although
routine use of prophylactic antibiotics is not recom-
mended for open, non-implant herniorrhaphy, there is
little direct clinical evidence on which to base recom-
mendations when an implantable mesh is used. No SSIs
occurred following 120 mesh herniorrhaphies performed
without routine antibiotic administration [26]; however,
the incidence of SSIs varies, depending on the different
case series, ranging from 1–2 % to 3–4 %.
Mesh infection, although infrequent, is a devastating
complication of mesh hernioplasties. The crude mesh in-
fection rate was 5 % in a recent meta-analysis. Statisti-
cally significant risk factors were smoking, American
Society of Anesthesiologists (ASA) score C3 and emer-
gency operation; mesh infections were also significantly
correlated with the patients’ age and the duration of the
Table 2 SSI epidemiology in Italy
Authors Country Period Number of surgeries SSIs
Petrosillo et al. Italy, multicenter 2002, Prospectively for one month in 48 hospitals 4.665 241 (5,2 %)
Marchi et al. Italy, multicenter 2009–2001, retrospective, 355 surgical departments 60.460 1.628 (2,6 %)
Fiorio et al. Italy, multicenter 2002, Prospectively for one month in 48 hospitals,
32 surgical departments
2.972 158 (5,2 %)
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hernioplasty. A trend toward higher mesh infection rates
was observed in obese patients. The usual causative or-
ganisms associated with cases of mesh infection are
Staphylococcus spp., especially S. aureus, Streptococcus
spp. (including group B streptococci), Gram-negative
bacteria (mainly Enterobacteriaceae), and anaerobic
bacteria (including Peptostreptococcus spp.) [25]. In a
study of mesh-related infections following incisional
herniorrhaphy, 63 % of the microorganisms isolated
were MRSA [27].
Table 4 shows the microbiology of prosthetic infection
after hernia or ventral mesh repair.
Theoretically, surgical treatment of infected mesh her-
nioplasties requires removal of the implant and then im-
plantation of a new mesh; conservative treatments, such
as drainage or sinus resection, are usually unsuccessful.
Tolino et al. reported on 51 operations to treat 32 pa-
tients with mesh infections: removal of the mesh, recur-
rence and bowel fistulas were described [28].
Every year in Italy there are probably about 1,700 in-
fections of inguinal hernioplasties and 4,000 infections
of ventral hernioplasties (for %1 and 10 % rates of infect-
ive complications, respectively). The role of S. aureus
and MRSA in the etiology of these complications is very
strong [28, 29].
Vascular surgery
The incidence of SSIs at the groin after vascular proce-
dures ranges from 3 % to 44 % [30]. Factors contributing
to the increased incidence of SSIs in this subset of pa-
tients include disruption of the lymphatic system, prox-
imity of the surgical site to the perineum and external
urinary organs, and prosthetic graft placement. It must
be emphasized that the groin area contains a substantial
number of lymph nodes which have a priority role in
draining the entire lower limb and an incorrect surgical
technique often leads to lymphorrhea with a subsequent
SSI. A SSI following vascular surgery is a complication
that may lead not only to healing problems, but also to
limb loss and the risk of death. Furthermore, it is as-
sumed to be a risk factor for deeper infections extending
to the graft, which are associated with catastrophic con-
sequences: a death rate between 15 % and 75 % and a
major amputation rate of up to 70 %. Even when treat-
ment is successful, the morbidity associated with vascu-
lar graft infection is considerable, the outcomes often
being worse than the natural history of the vascular con-
dition that led to implantation of the graft.
A SSI always implies prolongation of the time spent in
hospital, higher hospital costs and greater morbidity for
the patient. Groin incisions play a central role in various
vascular operations. In addition to their traditional use
in bypass procedures, endarterectomies and throm-
boembolectomies, more than 95 % of all percutaneous
interventions are performed via the femoral access. The
increasing prevalence of infections by multiresistant
bacteria has been associated with worsened outcomes.
Although the management of groin SSIs is well docu-
mented, there is little published information about the
incidence and classification of these infections. Many au-
thors consider that diabetes, as well as obesity, has a
relatively minor role in initiating groin wound infections.
Besides general aseptic measures, the only strategy that
significantly reduces the incidence of SSIs is prophylactic
systemic antibiotics, administered only preoperatively.
There is no “gold standard” treatment of these infec-
tions. The initial treatment generally includes surgical
debridement and antibiotics. Pharmacological therapy is
very often prolonged for several weeks but with uncertain
results. Secondary interventions have been attempted with
limited success; such interventions include rotational
flaps, wound vacuum-assisted closure, alginate dressing,
graft excision and extra-anatomic or in situ bypass or
patch replacement using autologous, rifampin-soaked or
silver-impregnated materials.
Thoracic surgery
Thoracic surgery includes a wide variety of operations
involving the lungs and pleural cavities, mediastinum,
oesophagus and neck.
Table 3 Probability to have a post-discharge SSIs according to
type of surgery performed
Surgery Ratio between post-discharge
SSIs and in-hospital SSIs
Vascular surgery 0
Breast surgery 3,4
Cesarean section 2,5
Cholecistectomy 1,2
Gastric surgery 0,4
Appendectomy 0,2
Colon surgery 0,1
Hernia repair 1,4
Abdominal hysterectomy 0,6
Vaginal hysterectomy 1
Table 4 Microbiology of prosthetic infection (1 day- > 1 year)
after haernia or ventral mesh repair
Microbiology of prosthetic infection (1 day- > 1 year) after haernia or
ventral mesh repair
Staphylococcus aureus 50–60 %
Staphylococcus spp 10–20 %
Enterococcus spp 10–20 %
Gram-neg 5–10 %
Pseudomonas, Streptococcus spp,
Mycobacteria spp, mixed flora
rare
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The most common surgical incisions in thoracic sur-
gery are thoracotomies, cervicotomies, and thoraco-
abdominal incisions; sternotomies are less common.
The overall incidence of SSIs in thoracic surgery has
been estimated to be around 2–4 %.
Esophageal surgery, especially when the indication is
cancer, is the operation most frequently complicated by
SSIs, accounting for up to 15 % of cases due to radical
dissection, difficult reconstruction, frequent concomitant
colonization, and patients being at higher risk because of
concomitant conditions (age, smoking, alcoholism,
malnutrition, etc.).
The most common procedure, thoracotomy for lung
cancer, has been estimated to be complicated by SSIs in
only 2 % to 5 % of cases. However, this type of SSI
can produce serious discomfort for the patient, due
to the need for ongoing medication, pain, difficulty
with breathing with the risk of developing more ser-
ious infections such as pneumonia, pleural empyema
and mediastinitis.
Most recently mini-invasive thoracic approaches and
video-assisted thoracoscopic surgery have reduced the
overall wound infection rate to a mean of 1.7 % [31].
Deep sternal infections in cardiothoracic surgery, des-
pite accounting only for 1–4 % cases, can be associated
with ten-fold higher mortality rate.
An American study from 2002 showed that risk factors
for deep and superficial chest SSIs after coronary artery
bypass surgery differ, suggesting different etiopathogen-
esis. However, some of the risk factors for thoracic SSIs
are well known, such as age, smoking, diabetes, obesity
and, in particular, chronic obstructive pulmonary disease
requiring pre-operative treatment with systemic anti-
biotics and nebulisers [32]. The need for neoadjuvant
chemoradiotherapy in advanced cancer is another in-
dependent risk factor.
It seems obvious that all the risk factors for post-
operative infections in such fragile patients become
even more critical because the infections are caused
by multi-resistant organisms. The main sources of
multi-resistant infections are Gram-positive bacteria,
particularly MRSA, but other sources, such as fungi,
are becoming increasingly common.
Orthopedic surgery
Because orthopedic procedures are performed in a var-
iety of inpatient and outpatient settings, increased vigi-
lance, strict adherence to aseptic technique, attention to
adequacy of reprocessing and management of intraoper-
ative breaches of sterile technique are vitally important
to ensure a safe and consistent standard of care.
According to the National Healthcare Safety Network
report, which includes data from 2006 to 2008 in the
USA, the total number of patients who develop SSIs
following any type of orthopedic surgery is somewhere
between 31,000 and 35,000 [33]. SSIs in orthopedic sur-
gery prolong total hospital stay by a median of 2 weeks
per patient, approximately double readmission rates, and
increase health care costs by more than 300 %. More-
over, patients with SSIs have substantially greater phys-
ical limitations and significant reductions in their quality
of life [33].
The rates of SSIs following orthopedic procedures ap-
pear to be increased when certain risk factors are
present. Risk factors can be either patient modifiable or
not modifiable and/or procedure-specific, in which case
they may again be modifiable or not modifiable.
Hair removal, perioperative normothermia, preoperative
skin preparation, nasal decolonization, health problems and
situations predisposing the patient to infection, skin anti-
sepsis, surgical hand antisepsis, antibiotic prophylaxis, air
quality, double gloves, traffic pattern gowns and drapes,
bone cement, and sterility assurance are key factors for
controlling the risk of infections.
Although the use of antimicrobial sutures is not rou-
tine practice, the benefits of this strategy are becoming
increasingly apparent [34]. Likewise, advances in anti-
microbial coatings for implants, instruments, equipment
and the environment may provide additional support
to reach the goal of no SSIs. The practice of prescre-
ening patients prior to surgery is recommended, as
part of a comprehensive program to eliminate SSIs in
orthopedic surgery, especially in cases involving an
implantable device.
Type of surgery and risk of surgical site infections
Attempts have been made to quantify the risk of SSIs
following types of surgery other than operations to the
abdominal wall..
De Lissovoy et al. performed a study with the aim of
analyzing the surgical procedures associated with the
highest rate of SSIs; they studied 723,490 discharges
from surgery units in 2005, identifying SSIs from the
presence of The International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) code
998.59. They divided surgical procedures into seven
categories: neurological; cardiovascular, colorectal, skin,
subcutaneous and breast; gastrointestinal, orthopedic
and obstetric-gynecological. This made it possible to
quantify the risk of SSIs according to the type of surgical
procedure used.
Table 5 lists the five most frequent surgical procedures
by category with respect to the incidence of SSIs.
Antimicrobial prophylaxis
The prevention of SSIs is an important issue in surgery.
Besides general strategies aimed at reducing the rate of
SSIs (hair removal, asepsis of the operating room,
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glucose control, blood transfusions, and smoking cessa-
tion) antibiotic prophylaxis plays a pivotal role in redu-
cing SSIs.
The degree of bacterial contamination during surgery,
together with the ASA score and duration of surgery,
define the appropriateness of antibiotic prophylaxis: sur-
gical procedures are classified, as well-known, into clean,
clean-contaminated, contaminated and dirty.
Dirty surgery should be treated as therapy of the infec-
tion involved (no prophylaxis).
Clean surgery usually does not need prophylaxis,
unless comorbidities are present and/or prostheses
are used.
The main indication for prophylaxis is, therefore,
clean-contaminated or contaminated surgery. The pur-
pose of antibiotic prophylaxis is only to avoid SSIs, not
Table 5 The 5 most frequent surgical procedures for categories with respect to the incidence of SSIs
Surgery category Procedure Percent of discharge Percent with SSI
Neurologic 03.59 Spinal structure repair not elsewhere classified 1,34 2.53
81.05 Other dorsolum fusion 0,27 2,29
02.12 Brain meninges repair not elsewhere classified 0,75 2,25
01.25 Other craniectomy 0,22 2,1
01.53 Brain lobectomy 0,29 2,09
Cardiovascular 35.14: Open heart valvuloplasty of tricuspid valve without replacement 0,3 4,32
35.84: Total correction of transposition of great vessels 0,35 4,09
35.91: Interatrial venous return transposition 0,08 3,85
37.22: Left heart cardiac catherization 0,17 3,74
35.28: Replace tricuspid valve not elsewhere classified 0,09 3,7
Colorectal 46.74: Closure small bowel fistula not elsewhere classified 0,28 10,0
45.93: Small-to-large bowel not elsewhere classified 0,55 9,24
45.61: Multiple segmental small bowel excision 0,55 8,73
46.20: Ileostomy not otherwise specified 0,19 8,59
46.01: Small bowel exteriorization 0,84 6,34
Breast
Skin and subcutaneous tissue
54.11: Exploratory laparotomy 0,5 2,5
84.15: Below knee amputation not elsewhere classified 0,32 1,96
40.11: Lymphatic structure biopsy 0,35 1,79
85.45: Unilateral radical mastectomy 0,6 1,57
54.30: Destruction abdominal wall lesion 0,42 1,49
Gastrointestinal 52.70: Radical pancreaticoduodenectomy 0,78 7,74
43.70: Partial gastrectomy with jejunum anastomosis 0,89 5,63
42.41: Partial esophagectomy 0,25 5,03
43.99: Total gastrectomy not elsewhere classified 0,49 4,99
86.22: Wound debridement 0,44 4,97
Orthopedic 80.05: Arthrotomy/prosthesis removal-hip 0,22 1,74
79.85: Open reduction-hip dislocatation 0,64 1,19
77.85: Partial ostectomy-femur 0,5 0,76
77.25: Femoral wedge osteotomy 0,55 0,69
80.15: Other arthrotomy-hip 0,88 0,66
Obstetric/
gynecologic
68.80: Pelvic evisceration 0,04 10,48
68.40: Total abdominal hysterectomy 0,03 4,3
40.54: Radical groin dissection 0,01 4,17
71.50: Radical vulvectomy 0,2 3,42
40.52: Radical dissection periaortic lymph node 0,08 2,3
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to prevent any other post-operative infectious complica-
tions (pneumonia, urinary tract infections, etc.).
The choice of antibiotic for prophylaxis should be di-
rected towards the more probable pathogens for the par-
ticular type of surgery. Furthermore, antibiotics with a
broad spectrum of action should not be used, because
such these are the drugs of choice to treat an infection
empirically.
Prophylaxis should be administered intravenously, half
an hour before the start of surgery and should not be
continued for more than 24 h.
Table 6 lists the recommended antibiotics for anti-
microbial prophylaxis [35] according to the type of sur-
gery, and the alternative drugs in case of allergy to
penicillin and/or cephalosporins. It is clear that the most
frequently used antibiotic is cefazolin alone, combined
with metronidazole when anti-anaerobe coverage is re-
quired and with vancomycin in selected cases of cardio-
vascular, orthopedic or neurosurgery when devices and/
or prostheses are used.
According to the guidelines, if the surgical proced-
ure lasts more than 3–4 h, there is an indication to
administer another dose of prophylactic antibiotic,
during surgery. In the case of renal impairment, this
interval should be modified according to the creatin-
ine clearance.
Therapy for methicillin-resistant Staphylococcus aureus
infections
The guidelines of the Infectious Diseases Society of
America recommend treatment with a beta-lactam or
clindamycin for mild/moderate, non-purulent ABSSSIs
and vancomycin plus piperacillin/tazobactam for severe,
non-purulent ABSSSIs [36]. Treatment of purulent
ABSSSIs should cover MRSA empirically with doxycyc-
line or trimethoprim/sulfamethoxazole in moderate
cases and vancomycin, daptomycin, linezolid, or ceftaro-
line in severe cases. With the increase of clinical MRSA
isolates with decreased susceptibility or resistance to
these drugs, treatment of ABSSSIs, especially SSIs, is
now challenged by antibiotic resistance, toxicity, few oral
options, and greater need for hospitalization and its as-
sociated costs [37]. Dalbavancin, a recent addition to the
antimicrobial armamentarium that could meet these
challenges, is a novel lipoglycopeptide approved by the
FDA in May 2014 and by the European Medicines
Agency (EMA) in February 2015 for ABSSSIs caused by
susceptible Gram-positive organisms [38].
Antimicrobials available in Italy for treating ABSSSIs
with activity against MRSA and other resistant Gram-
positive pathogens include vancomycin, teicoplanin, dap-
tomycin, linezolid, and ceftaroline. Of the antimicrobials
listed, only linezolid has an oral formulation, and some
have significant potential for toxicity, including renal im-
pairment from vancomycin, bone marrow suppression,
and drug interactions (e.g., selective serotonin re-uptake
inhibitors) from linezolid, and myopathy from daptomy-
cin. While doxycycline and trimethoprim/sulfamethoxa-
zole have MRSA activity, their activity against beta-
hemolytic streptococci is poorly, limiting their use as
monotherapy for ABSSSIs. Dalbavancin is a recently ap-
proved, novel lipoglycopeptide which could be an im-
portant addition to the antimicrobial armamentarium. It
has well-established activity against the Gram-positive
organisms commonly involved in superficial and deep
SSIs, including MRSA and other multidrug-resistant
pathogens, and the MIC90 values for these organisms
have remained stable over the past decade. Dalbavancin’s
Table 6 The recommendations for antimicrobial prophylaxis [30]
Surgical category Routine antibiotic prophylaxis Penicillin or cephalosporin allergy
Cardiac Cefazolin plus vancomycin (device only) Vancomycin or
Clindamycin plus gentamicin
Thoracic Cefazolin Vancomycin or
Clindamycin
Colorectal Cefazolin plus metronidazole Clindamycin plus gentamicin
Otorlaryngology Cefazolin alone or plus metronidazole Clindamycin alone or plus ciprofloxacin
General surgery Cefazolin Clindamycin alone or plus gentamicin
Hepatobiliary (complicated) Cefazolin Vancomycin plus tobramycin
Neurosurgery Cefazolin plus vancomycin (device only) Vancomycin
Orthopedic Cefazolin plus vancomycin (artroplasties only) Vancomycin or
Clindamycin
Obstetric/gynecologic Cefazolin Clindamycin
Vascular Cefazolin plus vancomycin (syntetic graft only) Vancomycin
Plastics, Reconstructive & Hand Surgery Cefazolin Clindamycin
Urology Cefazolin Ciprofloxacin alone or plus vancomycin
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high protein binding and prolonged half-life allow for
easily and consistently attainable therapeutic levels. Sev-
eral clinical trials have demonstrated its tolerability, effi-
cacy, and non-inferiority compared to standard therapy
for ABSSSIs. The DISCOVER 1 and DISCOVER 2 stud-
ies showed that once-weekly intravenous dalbavancin
was not inferior to twice-daily intravenous vancomycin
followed by oral linezolid for the treatment of ABSSSIs.
Adverse events were reported less frequently in patients
treated with dalbavancin than in those treated with
vancomycin–linezolid [39]. Indeed, dalbavancin’s most
unique feature is its once weekly dosing; thus far it had
been approved as a 1000 mg dose followed by 500 mg
1 week later.
Dalbavancin is also approved by the EMA for a
1500 mg, one-shot, single dose [40, 41].
Factors promoting its use as an anti-MRSA treatment are
its bactericidal activity, partial activity on biofilm increased
by combination with rifampin, no interactions and adverse
events and the possibility of an early discharge.
The main characteristics of anti-MRSA drugs used for
SSIs are reported in Table 7.
Methods
Three of us (GS, CT and SC) analyzed the literature on
the field of SSIs (randomized clinical trials, case–control
studies, recommendations and clinical cases) and pro-
posed some major and minor risk factors for SSIs to a
board of general and specialist surgeons. We used the
Delphi method [42–44] to make operative decisions
through different steps of convergence, depending on
the consensus reached in each round of consultation of
the board.
The board was composed of one vascular surgeon, one
orthopedic surgeon, one thoracic surgeon, six general
and emergency surgeons and one infectious diseases
specialist.
Results
We identified the major and minor risk factors for
MRSA SSIs using the Delphi method. The level of con-
sensus acceptable for approval by the group was more
than 80 %. Beside the risk factors we also identified pro-
tective factors for these kind of infections.
Table 8 reports the risk factors with rates of agreement
in the Delphi consultation.
These factors should be validated in prospective stud-
ies, in order to refine the identification of patients at
higher risk of developing MRSA SSIs or to identify pa-
tients with a SSI due to MRSA earlier so that effective
antibiotic therapy can be administered promptly.
Discussion
S. aureus is consistently the leading cause of nosocomial
infections, including SSIs, and the incidence of MRSA
strains is rising dramatically. Admissions to hospital be-
cause of MRSA infections have more than doubled in
the past decade, and MRSA is the leading cause of SSIs
in many academic and community hospitals [45].
Table 7 The main characteristics of anti MRSA drugs used for SSIs
Antibiotic Battericidal activity/Pharmacodynamic/
anti-biofilm activity
Route of
administration
Doses Adverse events Interaction Cost (70 kg)
Teicoplanin Bactericidal with low MIC/time
dependent/none
iv im 7-10 mg/Kg die,
loading dose
Renal toxicicty None 50–70 E/die
Vancomycin Bactericidal with low MIC/time
dependent/none
Iv 1 g x 2 die
500 mg x 4 die
Renal toxicicty Other nephrotoxic
drugs
5 E/die
Daptomycin Bactericidal/concentration
dependent/yes
Iv 4–6 mg/kg Tossicità muscolare Statine 80–120
E/die
Linezolid Bacteriostatic/time dependent/none Iv/oral 1200 mg die Bome marrow
toxicity, neuropathy,
serotoninergic
syndrome
SSRI 120 E/die
Tigecycline Bacteriostatic/time dependent/partial Iv 50 mg x 2
die; 100 mg
loading dose
Nausea, vomit,
pancreatitis
None 120 E/die
Ceftaroline Bactericidal/time dependent/none Iv 600 mg x 2 die rash None 96 E/die
Dalbavancin Bactericidal/concentration dependent/
partial (in association with rifampin)
Iv 1000 mg giorno
1, 500 mg giorno 7
No None NA
Cotrimoxazole Bactericidal/time dependent/none Iv, oral 800/160 mg 3
times a dai
anemia None 15 E/die
Rifampin Bactericidal/time dependent/yes Iv/oral 600 mg once
a day
Liver toxicity Several 6 E/die
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MRSA as a cause of a SSI was also shown to be a sig-
nificant independent risk factor for adverse economic
outcomes. The risk-adjusted attributable increase in dur-
ation of hospitalization was approximately 1 day and the
increase in hospitalization costs was over $1,000. Other
studies support the finding that patients with MRSA in-
fections require more health care resources than patients
with methicillin-sensitive S. aureus (MSSA) infections
[46]. Kirkland et al. estimated that the excess hospital
costs associated with MRSA SSIs ranged from $3,089 to
$35,367 [2]. Engemann et al. found that, among surgical
patients, those with MRSA infections were hospitalized
5 days longer than those with MSSA [47]. Hospital
charges for patients with MRSA infections were also
$62,908 greater than those for patients without an in-
fection and $40,000 greater than for patients with
MSSA infections.
Weigelt et al. found that significant independent risk
factors increasing cost and duration of hospitalization
SSIs due to MRSA included illness severity, transfer
from another health care facility, previous admissions
(within the preceding 30 days), and other polymicrobial
infections (p < 0.05) [48].
Because universal, rapid MRSA screening is not rec-
ommended by all authors, identifying patients at risk of
colonization by MRSA and subsequently of SSIs could
be very useful.
Harbarth et al. found that emergency surgery, presence
of comorbid condition, immunosuppressive therapy,
contaminated surgery, and a surgical duration longer
than the 75th percentile were the strongest risk factors
for MRSA colonization in surgical patients and these
factors were confirmed in a validation cohort. [49] We
also tried to identify risk factors for colonization and/or
infection by MRSA. We analyzed the literature in order
to list and quantify the risks of colonization and/or in-
fection by MRSA in surgical patients. The risk factors
and protective factors that emerged from Italian litera-
ture are presented in Table 9.
An algorithmic method may be useful for identifying
patients without risk factors (high negative predictive
model) but could be less useful for identifying true posi-
tive cases (low positive predictive value). We, therefore,
tried to assign a different importance to specific risk fac-
tors dividing them into major and minor risk factors for
MRSA infection in surgical patients in general and in
Italy in particular.
After a review of the specific literature, using the Del-
phi method we attempted to quantify the importance of
risk factors and protective factors for MRSA SSIs. This
information could be useful for a surgeon in the daily
evaluation of patients who have to undergo surgery or
patients who are suspected of having a SSI. This instru-
ment is not an alternative to the current, recommended
hygiene measures or to adequate, correctly timed anti-
biotic prophylaxis. In the case of a SSI, after debride-
ment of the wound and culture of the material obtained
from the wound, empirical antibiotic therapy should be
started, especially if there is a high risk that the patho-
genic agent is MRSA. Dalbavancin, with its long half-life
(186 h), should also be administered in the case of
programmed discharge of the patient. According to
the current summary of product characteristics, a sec-
ond dose is indicated after 7 days. This second ad-
ministration might also be a useful occasion for the
second surgical evaluation of the wound. Because
early discharge is almost always recommended for
surgical patients, dalbavancin could be a further
Table 8 Risk factors and protective factors according to italian literature
Risk factors Marchi et al.
OR
Petrosillo et al.
OR
Fiorio et al.
OR
Duration of surgery > 75 percentile (minor criteria) 1,52 – –
Hospitalization before major surgery >48 h
1,22
>24 h
1,45
>48 h
statistically significant
Urgent surgical intervention 1,29 1,73 –
ASA≥ 3 (minor criteria) 1,71 – –
Age > 70 years (major criteria) – 1,5 –
Drainage > 3 days – 2,17 –
NNIS score 2-3 – 3,34 –
diabetes (minor criteria) – – statistically significant
Obesity (minor criteria) – – statistically significant
Protective factors
Laparoscopy 0,49 – –
SSIs hospital with active surveillance for at least 2 years 0,71 – –
Adequate prophylaxis – 0,68 –
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beneficial tool to treat SSIs correctly, without increas-
ing the duration of hospitalization, especially for
those patients who require continued hospitalization
only to complete intravenous antibiotic therapy.
Conclusion
SSIs are still important diseases in the context of ABSS-
SIs. These infections have a strong impact from both
clinical and economic points of view. Therefore, in the
pre-operative and post-operative evaluation of patients
suspected of developing a SSI, recognizing whether the
patient has risk factors for a SSI and especially one
caused by MRSA, the most important pathogen in this
field, might be very important in the management of
surgical patients.
In the case of a SSI, after debridement of the wound
and culture of the material obtained from the wound,
empirical antibiotic therapy should be started especially
if there is a high probability of the pathogenic agent be-
ing MRSA. Dalbavancin, with its long half-life (186 h),
should also be administered in the case of programmed
discharge of the patient. A second dose is indicated
after 7 days according to the drug’s summary of prod-
uct characteristics.
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